title: Copeptin and risk stratification in patients with ischemic stroke and transient ischemic attack: the CoRisk study.
abstract: BACKGROUND
  Copeptin independently predicts functional outcome and mortality at 90 days and one-year after ischemic stroke. In patients with transient ischemic attack, elevated copeptin values indicate an increased risk of further cerebrovascular events.
  
  
  OBJECTIVE
  The Copeptin Risk Stratification (CoRisk) study aims to validate the predictive value of copeptin in patients with ischemic stroke and transient ischemic attack. In patients with ischemic stroke, the CoRisk study aims to further explore the effect of treatment (i.e. thrombolysis) on the predictive value of copeptin.
  
  
  METHODS
  Prospective observational multicenter study analyzing three groups of patients, i.e. patients with ischemic stroke treated with and without thrombolysis and patients with transient ischemic attack.
  
  
  RESULTS
  Primary end-point: In patients with ischemic stroke, the primary end-point includes disability (modified Rankin scale from 3 to 5) and mortality (modified Rankin scale 6) at three-months after stroke. In patients with transient ischemic attack, the primary end-point is a recurrent ischemic cerebrovascular event (i.e. ischemic stroke or recurrent transient ischemic attack). Secondary end-point: In patients with ischemic stroke, the secondary end-points include in-house complications (i.e. symptomatic intracerebral hemorrhage, malignant edema, aspiration pneumonia or seizures during hospitalization, and in-house mortality).
authors.affiliation: Department of Neurology, Inselspital, University of Bern, Bern, Switzerland.
authors.forename: Gian Marco
authors.initials: GM
authors.lastname: De Marchis
authors.forename: Mira
authors.initials: M
authors.lastname: Katan
authors.forename: Anja
authors.initials: A
authors.lastname: Weck
authors.forename: Caspar
authors.initials: C
authors.lastname: Brekenfeld
authors.forename: Heinrich P
authors.initials: HP
authors.lastname: Mattle
authors.forename: Daniela
authors.initials: D
authors.lastname: Buhl
authors.forename: Beat
authors.initials: B
authors.lastname: Müller
authors.forename: Mirjam
authors.initials: M
authors.lastname: Christ-Crain
authors.forename: Marcel
authors.initials: M
authors.lastname: Arnold
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D006233:Persons with Disabilities / Q000706:statistics & numerical data; D006020:Glycopeptides / Q000378:metabolism*; D017052:Hospital Mortality; D006801:Humans; D002546:Ischemic Attack, Transient / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D011446:Prospective Studies; D012008:Recurrence; D018570:Risk Assessment; D018401:Sample Size; D020521:Stroke / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D015912:Thrombolytic Therapy / Q000379:methods; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006020:Glycopeptides; C048197:copeptins